These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29005537)

  • 21. Natural history of leprosy--aspects relevant to a leprosy vaccine.
    Fine PE
    Int J Lepr Other Mycobact Dis; 1983 Dec; 51(4):553-5. PubMed ID: 6368419
    [No Abstract]   [Full Text] [Related]  

  • 22. Leprosy: a problem solved by 2000?
    Stearns AT
    Lepr Rev; 2002 Sep; 73(3):215-24. PubMed ID: 12449886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and pre-clinical assessment of a 73 kD chimeric fusion protein as a defined sub-unit vaccine for leprosy.
    Duthie MS; Sampaio LH; Oliveira RM; Raman VS; O'Donnell J; Bailor HR; Ireton GC; Sousa AL; Stefani MM; Reed SG
    Vaccine; 2013 Jan; 31(5):813-9. PubMed ID: 23228811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Relation between host resistance and disease type in murine leprosy. 9. Experiments in superinfection with murine leprosy in first generation hybrids of C3H and ddY mice].
    KAWAGUCHI Y
    Nihon Saikingaku Zasshi; 1962 Jun; 17():398-401. PubMed ID: 14031473
    [No Abstract]   [Full Text] [Related]  

  • 25. The BCG controversy: a reappraisal of the protective effect against tuberculosis and leprosy.
    Zodpey SP
    Indian J Public Health; 2004; 48(2):70-7. PubMed ID: 15709589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunization against leprosy: progress and prospects.
    Noordeen SK; Sansarricq H
    Bull World Health Organ; 1984; 62(1):1-6. PubMed ID: 6370487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The importance of the protein antigens of Mycobacterium leprae. Their potential use for the development of a vaccine against leprosy].
    Vega-López F; Macotela-Ruiz E
    Gac Med Mex; 1991; 127(1):31-9. PubMed ID: 1959737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long lasting BCG protection against leprosy.
    Rodrigues LC; Kerr-Pontes LR; Frietas MV; Barreto ML
    Vaccine; 2007 Sep; 25(39-40):6842-4. PubMed ID: 17728023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Perspectives on fighting leprosy].
    Janaszek W
    Przegl Epidemiol; 1991; 45(3):157-62. PubMed ID: 1819810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group.
    Lancet; 1996 Jul; 348(9019):17-24. PubMed ID: 8691924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune profiling of leprosy and tuberculosis patients to 15-mer peptides of Mycobacterium leprae and M. tuberculosis GroES in a BCG vaccinated area: implications for development of vaccine and diagnostic reagents.
    Hussain R; Shahid F; Zafar S; Dojki M; Dockrell HM
    Immunology; 2004 Apr; 111(4):462-71. PubMed ID: 15056384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Problems in designing a protocol for a leprosy vaccine trial. (author's transl)].
    Sansarricq H
    Rev Epidemiol Sante Publique; 1981; 29(3):305-14. PubMed ID: 7029677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Borderline tuberculoid leprosy following BCG vaccination. A case report.
    Stoner GL; Belehu A; Nsibambi J; Warndorff J
    Int J Lepr Other Mycobact Dis; 1981 Mar; 49(1):16-20. PubMed ID: 7195879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BCG vaccination in leprosy: final results of the trial in Karimui, Papua New Guinea, 1963-79.
    Bagshawe A; Scott GC; Russell DA; Wigley SC; Merianos A; Berry G
    Bull World Health Organ; 1989; 67(4):389-99. PubMed ID: 2680140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disabilities in multibacillary leprosy following multidrug therapy with and without immunotherapy with Mycobacterium w antileprosy vaccine.
    Sharma P; Kar HK; Misra RS; Mukherjee A; Kaur H; Mukherjee R; Rani R
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):250-8. PubMed ID: 10575404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of BCG in prevention of leprosy: a meta-analysis.
    Setia MS; Steinmaus C; Ho CS; Rutherford GW
    Lancet Infect Dis; 2006 Mar; 6(3):162-70. PubMed ID: 16500597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective efficacy of BCG against leprosy in São Paulo.
    Lombardi C; Pedrazzani ES; Pedrazzani JC; Filho PF; Zicker F
    Bull Pan Am Health Organ; 1996 Mar; 30(1):24-30. PubMed ID: 8919722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pilot study of three potential vaccines for leprosy in Bombay.
    Ganapati R; Revankar CR; Lockwood DN; Wilson RC; Price JE; Ashton P; Ashton LA; Holmes RM; Bennett C; Stanford JL
    Int J Lepr Other Mycobact Dis; 1989 Mar; 57(1):33-7. PubMed ID: 2659699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Scar size and effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of tuberculosis and leprosy: a case-control study.
    Zodpey SP; Shrikhande SN; Kulkarni SW; Maldhure BR
    Indian J Public Health; 2007; 51(3):184-9. PubMed ID: 18229442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 'Isopathic phenomenon' in leprosy.
    Rao BN; Satyanarayana BV; Venkatarathnam G; Reddy CR
    Dermatologica; 1975; 150(3):169-75. PubMed ID: 1158013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.